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Abstract
Cytokine mediated inflammation likely plays an important role in secondary pathology after traumatic brain injury (TBI).
The aim of this study was to elucidate secondary cytokine responses in an in vitro enriched (>80%) human stem cell-
derived neuronal model. We exposed neuronal cultures to pre-determined and clinically relevant pathophysiological levels
of tumor necrosis factor-a (TNF), interleukin-6 (IL-6) and interleukin-1b (IL-1b), shown to be present in the inflammatory
aftermath of TBI. Data from this reductionist human model were then compared with our in vivo data. Human embryonic
stem cell (hESC)-derived neurons were exposed to recombinant TNF (1–10,000 pg/mL), IL-1b (1–10,000 pg/mL), and IL-
6 (0.1–1000 ng/mL). After 1, 24, and 72 h, culture supernatant was sampled and analyzed using a human cytokine/
chemokine 42-plex Milliplex kit on the Luminex platform. The culture secretome revealed both a dose- and/or time-
dependent release of cytokines. The IL-6 and TNF exposure each resulted in significantly increased levels of >10
cytokines over time, while IL-1b increased the level of C-X-C motif chemokine 10 (CXCL10/IP10) alone. Importantly,
these patterns are consistent with our in vivo (human) TBI data, thus validating our human stem cell-derived neuronal
platform as a clinically useful reductionist model. Our data cumulatively suggest that IL-6 and TNF have direct actions,
while the action of IL-1b on human neurons likely occurs indirectly through inflammatory cells. The hESC-derived
neurons provide a valuable platform to model cytokine mediated inflammation and can provide important insights into the
mechanisms of neuroinflammation after TBI.
Keywords: cytokine exposure; human embryonic stem cell-derived neurons; interleukin-1b; interleukin-6; in vitro; tumor
necrosis factor
Introduction
Traumatic brain injury (TBI) is a common cause of deathand disability.1 After initial impact, subsequent insults such as
impaired cerebral perfusion and disrupted oxygen supply can cause
secondary injuries and an increasingly neurotoxic environment for
surviving cells.2,3 These secondary injuries have been shown to be
mediated in part by components of the innate immune system,4,5
with inflammatory cytokines being specifically implicated.6,7 The
cytokine response orchestrating subsequent neuroinflammation in
human TBI seems to be determined both temporally and in a dose-
dependent manner.8,9 Moreover, while it is possible that the in-
flammatory process is driven at least partly by cells crossing the
impaired blood–brain barrier in TBI and spinal cord injury,10,11
there is evidence of local cytokine generation by glial cells, central
nervous system (CNS) macrophages, and neuronal cells.8,12,13 In
animal models, neuronal cells have been shown to produce cyto-
kines, both spontaneously and after external stimuli.7,14–16 Studies
of TBI using human neuron models with exposure to cytokines are
scarce, however.17
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Clinically, cytokines extracted using microdialysis catheters18
are secreted by the local cellular milieu.8 The inflammatory re-
sponse in TBI is complex and difficult to study because of factors
such as the heterogeneity between different CNS injuries and
the limited tools available in the clinical setting.4 Moreover, even
by using in vitro co-cultures of neurons and glial cells, the in-
tricate interplay between different inflammatory reactive cells
remains,7,12,19 thus complicating interpretation. A reductionist ap-
proach using human neuronal monoculture provides an opportunity
to directly study specific components of the neuroinflammatory re-
sponse after TBI, because it allows direct comparisons to be made
between the actions of various cytokines in a highly controlled and
reproducible system.
The aim of this study is to investigate the consequences of
specific cytokines most widely studied in the TBI literature—
namely, interleukin-1 beta (IL-1b), interleukin-6 (IL-6), and tumor
necrosis factor alpha (TNF)20 in human neurons in a dose and
time-dependent manner. Specifically, we focused on elucidat-
ing secondary cytokine responses to primary canonical pro-
inflammatory cytokine exposure, and we validate these data against
cytokine patterns seen in the clinical aftermath of TBI. We over-
come the inaccessibility to human neuronal models by harnessing
directed differentiation of human pluripotent stem cells, which
represent a reductionist, reliable, and clinically relevant model
system.
Methods
Human embryonic stem cell culture
The methods used to generate neuronal cells have been de-
scribed previously in detail and used in previous studies.21,22
Briefly, two human embryonic stem cell (hESC) lines, H9 (WiCell
Research Institute) and HuES9 (hES facility, Harvard University)
were propagated on a layer of irradiated mouse fibroblasts. These
cells were enzymatically dissociated, mechanically triturated,
centrifuged, and washed and resuspended in medium consisting of
50% Iscove modified Dulbecco medium (IMDM; Gibco) plus 50%
F12 plus Glutamax (Gibco), supplemented with 1.75mM human
recombinant insulin (Roche), 0.38mM transferrin (Roche), 450lM
of monothioglycerol (Sigma), 10lL/mL-1 lipids (Sigma), and
5mg/mL-1 bovine serum albumin fraction V (Sigma).
To generate neural precursors, previously published methods
were adapted to generate predominantly (approximately 80%) ce-
rebral neurons.21,22 Detached colonies were centrifuged subse-
quently and washed in fresh medium. Colonies were next chopped
at 150lm intervals using a McIlwain tissue chopper (Mickle En-
gineering, Gomshall, U.K.) before being plated at low density in
chemically definedmedium,which consisted of 50% IMDM (Gibco)
plus 50% F12 plus Glutamax (Gibco), 1.75mM human recombinant
insulin (Roche), 0.38mM transferrin (Roche), 450mM of mono-
thioglycerol (Sigma), 10mg/mL lipids (Gibco), and 5mg/mL bovine
serum albumin fraction V (Sigma) in 10-cm plastic culture dishes on
an orbital shaker. Neural precursors (NPCs) were maintained in
chemically defined medium in the presence of 20 ng/mL of FGF2
from day 8.
For terminal differentiation, hESC-NPCs were plated onto
poly(d-lysine)/laminin-coated coverslips and cultured in Dulbecco
modified Eagle medium (DMEM)/2% B27/1% penicillin/streptomy-
cin/fungizone (PSF), 10 ng/mL-1 BDNF (brain-derived neurotrophic
factor; R&D Systems) and 10 ng/mL-1 GDNF (glial cell-derived
neurotrophic factor; R&D Systems) in the absence of mitogens.
Cells were incubated at 37C in 5% CO2 with replacement of the
culture medium every 72 h. Cells were cultured within 24 well
plastic plates on coverslips in which the volume of culture me-
dium was kept at 1mL per well.
Experimental conditions
Human recombinant IL-1b, IL-6, and TNF (Peprotech EC, Lon-
don, UK) was sourced as lyophilized powder, which was recon-
stituted according to the manufacturer’s instructions. Serial dilution
of this stock solution generated the various concentrations required
to generate the final concentrations in Table 1 within the 1mL wells.
Each cytokine was used at four concentrations covering the range of
concentrations seen within human microdialysis studies after cor-
rection for relative recovery determined in vivo,8 as well as covering
higher doses that might be seen in the early phase of injury before
microdialysis monitoring is instituted. Control wells with untreated
cells were also sampled to provide a comparator group.
The cytokine solution (10 lL) was added to 990 lL of culture
within each well to make up the desired final concentration within
1mL at the time of medium replacement. Cell cultures were then
returned to an incubator. Samples were taken as detailed below.We
used two different hESC lines, and 2–3 separate neural inductions
per line, giving us 3–5 repeats for each experiment.
Sample collection and storage
Samples (60lL) were taken from each well culture supernatant at
the given time points. Five baseline sampleswere taken before adding
any cytokine. Further samples were taken at 1 h, 24 h, and 72h after
addition of the respective cytokine (n=3 per time point). When
performing the experiments, seeding density was 100,000 cells per
well of a 24-well plate. Samples were stored at -80C until analysis.
Cytokine analysis
The cell culture supernatants from three wells for each ex-
perimental condition were analyzed in duplicate wells using the
MilliplexTM MultiAnalyte Profiling (MAP) Human Cytokine/
Chemokine 42 analyte pre-mixed kit (Millipore Corp, St. Louis,
MO) using the manufacturer’s instructions as described previ-
ously.23 The plates were read on a Luminex 200 analyzer (Lu-
minex Corporation, Austin, TX) running STarStation software
(Applied Cytometry Systems, Sheffield, UK). Cytokine concen-
trations were calculated by reference to an eight-point five-
parameter logistic standard curve for each cytokine.
Immunocytochemistry
Neurons were differentiated on poly-D-lysine/laminin coated
glass coverslips. These were fixed with 4% fresh paraformaldehyde
for 20min at room temperature before being washed three times
with phosphate-buffered saline (PBS). Samples were then blocked
for 1 h at room temperature with 0.3% Triton/ PBS/5% goat serum
before being incubated overnight with primary antibody in 0.2%
Triton/PBS/2% goat serum at 4C. After three washes in PBS,
secondary antibody (goat anti-mouse, Alexa Fluor 488 or 555,
1:1000) in PBS/Hoechst (1:4000) was next applied for 1 h at room
temperature. Primary antibodies used included b-III tubulin (1:500;
Sigma- Aldrich), orthodenticle homeobox 1 (OTX1), REELIN, T-
Box Brain 1 [TBR1] (1:50; Developmental Studies Hybridoma
Bank [DSHB], Iowa City), Forkhead Box G1 (FOXG1) (1:100;
Abcam), Synapsin (1:500; Calbiochem), microtubule associated
protein 2ab (MAP2ab) (1:500; Sigma-Aldrich), gamma-aminobutyric
acid (GABA) (1:500; Sigma-Aldrich) and glutamate (1:500; Sigma-
Aldrich).
Clinical cytokine data from patients with TBI
We extracted data from two previously published studies from
our group describing the temporal profiles and concentrations of
cytokines from patients with severe TBI.8,24 In a pilot trial of IL-1
receptor antagonist treatment for TBI, we used brain cytokine
concentrations from the placebo group.24 Demographic data for all
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patients are available in Supplementary Table 1 (see online sup-
plementary material at ftp.liebertpub.com), including age, sex,
admission Glasgow Coma Scale (GCS) and head computed to-
mography (CT) verifiable injury as defined by Marshall CT clas-
sification (Grade II–IV = diffuse and Grade VI = focal).25 As
described in detail in the previous studies,8,24 patients were moni-
tored for approximately five consecutive days, and cytokine sam-
ples were pooled from 6-h periods. While there was some disparity
in commencement of monitoring after the traumatic ictus, all data
have been corrected to the time of injury to enable comparison with
the in vitro experiments.
Statistical analysis
The effect of each of the added cytokines (IL-1b, IL-6, TNF) on
the measured cytokines (42 cytokine panel) was analyzed using
Table 1. Summary of Significant Effects of Added Cytokine on Measured Cytokines
Cytokine measured
IL-1b Added IL-6 Added TNF-a Added
Conc. 1 h 24 h 72 h Conc. 1 h 24 h 72 h Conc. 1 h 24 h 72 h
EGF X
Eotaxin X
FGF2 X
Flt3lig
Fractalkine X X X
G-CSF
GM-CSF X X X
GRO X X
IFNa2 X X
IFNc X X X
IL-1a X X X
IL-1b
IL-1ra X
IL-2
IL-3
IL-4 X
IL-5 X X
IL-6 X
IL-7 X X X X X
IL-8 X X
IL-9
IL-10 X X
IL-12p40 X X X X
IL-12p70 X X X
IL-13 X X
IL-15
IL-17
IP-10 X X
MCP-1
MCP-3 X X
MDC
MIP1a X
MIP1b X X X
PDGFAA
PDGFABBB X
RANTES X X X X
sCD40L X X
sIL-2Ra X
TNF-a
TNF-b X X X
VEGF
EGF, epidermal growth factor; FGF2, fibroblast growth factor 2; Flt3lig, Fms-related tyrosine kinase 3 ligand; G-CSF, granulocyte colony-stimulating
factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; GRO, chemokine (C-X-C motif) ligand 1 (CXCL1); IFN, interferon; IL,
interleukin; IL-1ra, interleukin-1 receptor antagonist; IP-10/IP10, interferon gamma-induced protein 10 (also known as C-X-C motif chemokine 10
(CXCL10)); MCP-1, monocyte chemotactic protein 1 (also known as CCL2); MCP-3, monocyte chemotactic protein-3 (also known as CCL7); MDC,
macrophage-derived chemokine (also known as CCL22); MIP1a, macrophage inflammatory protein 1 alpha (also known as CCL3); MIP1b, macrophage
inflammatory protein 1 beta (also known as CCL4); PDGF, platelet-derived growth factor; RANTES, regulated on activation, normal T cell expressed and
secreted (also known as CCL5); sCD40L, soluble CD40 ligand; sIL-2Ra, soluble Interleukin-2 receptor antagonist; TNF, tumor necrosis factor; VEGF,
vascular endothelial growth factor.
The columns with bold borders represent each of the experimental conditions (IL-1b, IL-6, and TNF-a). Within these headings, cytokine induction only
affected by concentration difference (‘‘Conc.’’) of the added cytokine, as well as on each individual time point (1 h, 24 h, 72 h), are tested in a multivariate
analysis of variance. The concentration or time dependent induction of a given cytokine is highlighted with an X if significant ( p< 0.05). Detailed
description of the analyses performed is available in Supplementary Figure 1.
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a two-way mixed analysis of variance (ANOVA) (to compare
concentrations of each cytokine analyzed). The time at which the
sample was taken (‘‘Time’’; 0 (baseline levels), 1 h, 24 h, 72 h) was
used as the repeated measure (within subject) variable. The con-
centration of added cytokine (‘‘Concentration’’; untreated, and four
concentrations of added cytokine in Table 1) was used as the inde-
pendent (between subject) variable. No assumptions were made
about sphericity of the data, and the more conservative Greenhouse-
Geisser method was used to determine the F-ratio significance value
for the effect of Time and the interaction of time and concentration
(‘‘Time*Concentration’’). The conventional ANOVA F-ratio sig-
nificance value was used for the independent variable ‘‘Concentra-
tion.’’ For those cytokines in which the ANOVA significance value
was <0.05, post hoc tests were used to explore the nature of this
contrast.
Tests of contrast within ‘‘Time’’ and the interaction of ‘‘Time*-
Concentration’’ were tested against three potential models: linear,
quadratic, and cubic. The model with the most stringent p value is
quoted. In cases where the p values are identical, the relevant models
are listed. In the case of Concentration, the Bonferroni multiple
comparison test was used to determine significance values between
each of the added concentrations.
In a separate analysis, we have compared the effects of the three
added cytokines in a multivariate ANOVA in which the dependent
variables were the measured cytokines at three time points (i.e.,
cytokine measured at 1 h, cytokine measured at 24 h, and cytokine
measured at 72 h) and the independent variable was the cytokine
added (No cytokine added, IL-1b, IL-6, TNF). In this case, the data
from the control wells with untreated are not incorporated into the
series of concentrations but are compared as a separate group:
‘‘untreated.’’ For the F-ratios and post hoc tests described above, a
p value of £0.05 has been used throughout.
Descriptively, we compared the temporal profiles of cytokine
release as well as concentrations in vivo from a previous study and
compared them with our results.8,24
Results
hESC-derived neuronal cultures
After neural induction, we detected 95.0 – 1.5% NESTIN posi-
tive cells (Fig. 1), suggesting efficient neural conversion consistent
with previous studies.21,22 This was reinforced by a high enrich-
ment of neurons on terminal differentiation; 84.1 – 1.6% of total
cultures were bIII-tubulin positive and exhibited characteristic
neuronal morphology (Fig. 2A,B). Notably only 2.9 – 0.6% of total
cells were glial fibrillary acidic protein (GFAP) positive (Fig. 1),
confirming a minimal presence of astrocytes. Less than 1% of the
resulting cultures were O4 positive, suggesting negligible oligo-
dendrogenesis (data not shown), which when considered together
with approximately 3% astrocyte specification is consistent with
the predominantly neuronal (rather than glial) potential of neural
precursors soon after neural induction.
The terminally differentiated neuronal cultures also expressed
synapsin, glutamate, GABA andMAP2ab (Fig. 2C). In line with the
expected/default telencephalic neuronal fate, we also confirmed the
expression of cortical neuronal markers including TBR1, OTX1,
REELIN, and FOXG1 (Fig. 2D). This enriched neuronal population
containing cortical derivatives serves as a reductionist human
in vitro model for further study.
Induction of cytokine response
Cytokine generation from the enriched neuronal cultures was
induced by exogenously adding escalating concentrations of IL-1b,
IL-6, and TNF analogous to the aftermath of TBI (Fig. 3A–C). The
concentrations of exogenously added cytokines are maintained
across all time points during the experimental period (Fig. 3). All
cytokines assayed were detected at some point within our experi-
mental paradigm, other than transforming growth factor beta
(TGFb).
Temporal and concentration dependent effect
of cytokine-stimulated neuronal cultures
IL-6 and TNF induction resulted in a concentration and time
dependent increase of 15 and 11 cytokines, respectively, while IL-
1b only showed a concentration dependent induction for IP10
(Table 1). Moreover, cytokine responses to IL-6 and TNF induction
were in general different, only overlapping for IL-7. Table 1
summarizes the results from the relevant post hoc tests regarding
the effects of adding each of the three cytokines on measured cy-
tokine at different concentrations and at each of the time points.
Supplementary Table 2 summarizes the results of the relevant post
hoc tests from the two-way mixed ANOVA performed for each
cytokine (Supplementary Table 2 and Supplementary Fig. 1; see
online supplementary material at ftp.liebertpub.com).
Patterns of cytokine release
Some cytokines are produced in a concentration dependent
fashion (Fig. 4A, pattern 1). Conversely, some are produced at a
given time in response to the added cytokine but do not show a
statistically significant effect in response to increasing concentra-
tions of primary cytokine exposure (Fig. 4B, pattern 2). A further
pattern was observed where cytokines show both a time and a
concentration dependency (Fig. 4C, pattern 3). Table 2 summarizes
these three patterns of cytokine production after cytokine exposure,
FIG. 1. Percentage immunopositive cells after neural induction
for NESTIN (95.0 – 1.5%) and on terminal differentiation for bIII-
tubulin (84.1 – 1.6%) and glial fibrillary acidic protein (GFAP)
(2.9 – 0.6%). Bars represent mean – standard error of the mean.
NPCs, neural precursors.
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which are exemplified for a subset of cytokines produced in response
to IL-6 (Fig. 4). Similar principles, however, are applicable across a
wider range of cytokines (Table 2 and Supplementary Fig. 1).
Cytokine temporal patterns in vivo vs. in vitro
In previous studies, we have characterized a time-resolved cy-
tokine response after TBI.8,24,26 We compared the time dependent
increase in the present study with our previous data (Table 3).8
Several cytokines, including IL1ra, IL6, IL7, IL8, GRO, MIP1b,
and RANTES exhibit similar levels in vivo as they do in our in vitro
model. The concentrations of cytokines were consistently higher
in the in vivo study,24 with some selected cytokines exhibiting a
strikingly higher concentration in vivo than others (factor >100 · )
(i.e., G-CSF). Other cytokines had a more modest increase (e.g.,
RANTES factor 5-10x; Table 3).
Discussion
We have established a reproducible platform to measure the
secondary cytokine responses in human enriched cortical neurons
subjected to primary canonical pro-inflammatory cytokines. Im-
portantly, we based our target concentration ranges on previously
determined human TBI conditions. We demonstrated that a wide
range of inflammatory mediators is differentially induced by the
addition of IL-6 and TNF and that the response was both time- and/
or concentration-dependent. Conversely, IL-1b only induced IP10,
which likely reflects the absence of glia in our neuronal culture
paradigm. Compared with the clinical conditions in brain extra-
cellular fluid (ECF), however, our cytokine concentrations were
lower, which is again likely attributable to the contribution of glial
cells to the neuroinflammatory response, and argues for future
studies focusing on astrocytes and microglia.
The principal CNS immune mediators are long-held to be mi-
croglial cells,27 while more recently a potent role of astrocytes has
been shown,28–30 with an intricate interplay between these cell
types.31,32 Studies on neurons as immunocompetent cells are
scarce, but it has been shown that they can produce major histo-
compatibility complex (MHC) 1 mRNA in response to inflamma-
tory (interferon [IFN]c) stimulation,33 which results in diverse
immunological responses to different stimuli.34,35 Moreover, it has
been suggested that the immunological actions of neurons could
cause ongoing neuroinflammation in neurodegenerative dis-
eases,36,37 which could in theory be initiated, or augmented, by
TBI. Importantly, while an increase of commonly considered pro-
inflammatory cytokines such as IL-1b and IL-6 have been associ-
ated with an unfavorable outcome for patients with TBI,38,39 we
believe it would be overly simplistic to draw conclusions from
individual cytokine levels because of the complex and dynamic
FIG. 2. (A) Phase contrast image ( · 200) showing the enriched neuronal cultures that were used in the experiments. (B) Illustrates
immunocytochemistry of the neuronal culture with bIII-tubulin stained neurons (green) and DAPI (blue) as cellular counterstaining
(scale bar: 50lm). (C) Confirms neuronal and neurotransmitter markers by staining for synapsin, glutamate, MAP2ab, and GABA (red),
DAPI (blue), and bIII-tubulin (green) (scale bar: 50lm). (D) Illustrates cortical markers, resulting as a default regional identity after
neural induction by staining for FOXG1, OTX1, TBR1, and REELIN (scale bar: 25lm). bIII-tubulin, Beta-III-tubulin; DAPI, 4’,6-
diamidino-2-phenylindole; MAP2ab, microtubule associated protein 2ab; GABA, gamma-aminobutyric acid; FOXG1, Forkhead
Box G1; OTX1, orthodenticle homeobox 1; TBR, T-Box, Brain 1.
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cellular interplay that orchestrates the inflammatory response. In-
deed, these processes have been shown to exert both harmful and
beneficial capabilities after brain injury.40,41
In this study, we have deliberately chosen not to separate
downstream assayed cytokines into pro- and anti-inflammatory
groups. Moreover, to give cytokines a distinctively pro- and anti-
inflammatory role might not be accurate,42 and from our experi-
ences using anti-inflammatory treatment (IL-1 receptor antagonist
in TBI), the response is complex, and different pathways and
clusters may form making it difficult to determine specific in-
flammatory preference.26 Thus, we looked at patterns incorporating
several cytokines, a similar approach as we recommend in the
clinical situation.43,44 In summary, we observed production of
different patterns of cytokines in enriched human cortical neuronal
cultures after cytokine induction, which may alter pathophysio-
logical processes in both potentially beneficial and unfavorable
ways in the in vivo situation.
While it has been shown that cultured cells of the CNS produce
cytokines,12,45,46 this has been in a disparate range of cultures.
Previously, cultured rat sympathetic ganglia and rat dorsal root
ganglia have been shown to produce cytokines (IL-1b and IL-
6),13,15 mouse embryonal neurons have been induced with cyto-
kines where IL-6 and chemokines IP10/CXCL10, MCP-1/CCL2,
and KC/CXCL1 concentrations were assessed,16 and rat pyramidal
neurons have shown IL-6 mRNA production.14 To our knowledge,
however, this is the first study to utilize enriched human neuronal
cultures, specifically with a cortical phenotype, in this context.
This study provides a translational, complementary in vitro
system to parallel our ongoing clinical research in human subjects.8
Moreover, because of logistical reasons, it is difficult to measure
the inflammatory response the first hours after trauma in patients
with severe TBI.8 Based on the animal literature, the initial hours
after trauma usually present the highest levels of key cytokines,47–49
and given that anti-inflammatory treatments in TBI are highly
sought after,50 the current in vitro platform holds promise for future
translational work. Further, one of the main benefits of a hESC
system is that it may be used to study further applied clinical
scenarios, such as cytokine inhibitors,51 on functional conse-
quences and cytokine expression patterns. In aggregate, while
nonhuman neuronal cultures have been shown to generate cyto-
kines, we present an in vitro model of enriched human cortical
neuronal cultures that may be used to investigate inflammatory
mediators, serving as a valuable pre-clinical model for putative
TBI therapies.
While both IL-6 and TNF exposure induce a wide range of
inflammatory cytokines, chemokines, and growth factors, IL-1b
did not induce any downstream cytokines in our neuronal cultures
other than IP10. An increase in IP10 has been shown previously by
Tsakiri and colleagues,16 using mouse embryonic neuronal cultures
exposed to IL-1. They reported an increased production of several
additional other cytokines, however, which could be attributed to
the higher concentrations of IL-1 used (mg/mL instead of ng/mL
FIG. 3. Illustrating the different concentrations of cytokines (y-
axis log, error bar illustrates mean– standard error of the mean)
that were used for (A) IL-1b, (B) IL-6, and (C) TNF over time (1,
24, and 72 h x-axis). As can be seen in the Panel legends, the
different colors of the lines are escalating concentrations of the
added cytokine. The same colors/concentrations also are present
in Supplementary Figure 1. IL, interleukin; TNF, tumor necrosis
factor.
‰
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and pg/mL in our study), thus not representative of clinically rel-
evant levels.8,16 Using embryonic murine cortical neurons in vitro,
Ringheim and colleagues52 noted that IL-1 and TNF stimulation led
to IL-6 and IL-6 mRNA production in the cells. Of the two, TNF
stimulation led to greater increase, but similar to the study by
Tsakiri and colleagues,16 they also used higher, nonphysiological
concentrations of IL-1 and TNF.
Our finding that IL-1b induced a limited cytokine response may
reflect a relative paucity of IL-1 receptors (IL-1R) on the neuronal
population. We analyzed RNA sequencing data from equivalently
enriched neuronal and astrocyte cultures derived from human
pluripotent cells53 to investigate IL-1R 1 (IL1R1) and IL-1 receptor
accessory protein (IL1RAP) expression. The IL1RAP plays an
essential role for IL1R1 signaling in the brain,54 making them es-
sential to assess together. We found that IL1R1 and IL1RAP were
similarly expressed in neurons, but exhibited lower expression than
in astrocyte cultures (Supplementary Fig. 2; see online supple-
mentary material at ftp.liebertpub.com).
FIG. 4. Mean sCD40L (A), MIP1a (B), and IL-12p70 (C) concentrations as induced by IL-6 to exemplify the different release patterns
of a concentration dependent, a time dependent, and a time and concentration dependent release of cytokines (as seen in Table 3). Bars
representing escalating concentration as seen in the legend included and is mean – standard error of the mean. sCD40L, soluble CD40
ligand; MIP1a=macrophage inflammatory protein 1 alpha; IL, interleukin.
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Further, it has been shown that IL-1b is not directly toxic in
neuronal cell culture in the absence of glia,51,55 suggesting that
neurons may not be the primary site of action of IL-1b in this
context, consistent with higher receptor mRNA levels in enriched
astrocyte cultures. Previously, neurons have been shown to produce
higher levels of IL-1b with other glial cells, such as astrocytes and
microglia,56 where IL-1b has been shown to demonstrate a potent
dose-dependent neurotoxic effect.51,57 Alternatively, using indi-
vidual IL-1b treated astrocytic culture supernatant on a human fetal
neuron culture also induced neuronal death.55 In a further human
fetal neuronal/glial co-culture model, IL-1b and TNF did not show
neurotoxic effects in isolation but caused neuronal death in com-
bination.58 In a similar model system, IL-1b and IFNc also dem-
onstrated a synergistic neurotoxic effect, possibly via induction of
TNF.19 In contrast, IL-6 has been shown more commonly to have
a neurotrophic action; however, like many cytokines, the exact ac-
tions are dependent on culture model, duration, and concentration
of exposure.59,60 In aggregate, IL-1b exposure did not lead to the
same extent of cytokine production as IL-6 and TNF, which could
be because of the enriched neuronal monoculture setup.
Cytokines that increased over time after exposure to different IL-
6 and TNF concentrations differed greatly, only really overlapping
Table 2. Summary of Cytokine Induction
Cytokine
added
Cytokine induced
Pattern 1
(concentration
dependent)
Pattern 2
(time dependent) Pattern 3 (time and concentration dependent)
IL-1b IP10
IL-6 IL-1a, IL-4, sCD40L IL-1ra, IL-5, IL-13, MIP1a,
RANTES
EGF, FGF-2, Fractalkine, GM-CSF, IFNa2, IFNc, IL-7,
IL-12p40, IL-12p70, MIP1b, sIL-2Ra, TNFb
TNF Eotaxin, GM-CSF, IP10 Fractalkine, IL-6, IL-10,
PDGF ABBB
GRO, IL-1a, IL-7, IL-8, MCP3, MIP1b, RANTES, sCD40L
IP-10, interferon gamma-induced protein 10; sCD40L, soluble CD40 ligand; MIP1a, macrophage inflammatory protein 1 alpha; RANTES, regulated
on activation, normal T cell expressed and secreted; EGF, epidermal growth factor; FGF2, fibroblast growth factor 2; GM-CSF, granulocyte-macrophage
colony-stimulating factor; IFN, interferon; MIP1b, macrophage inflammatory protein 1 beta; sIL-2Ra, soluble interleukin-2 receptor antagonist; PDGF,
platelet-derived growth factor; MCP-3, monocyte chemotactic protein-3.
The three patterns of cytokine induction detected after interleukin (IL)-1b, IL-6, and tumor necrosis factor (TNF) exposure. Pattern 1: concentration
dependent but time independent cytokine response; Pattern 2: time dependent but concentration independent cytokine response; Pattern 3: time and
concentration dependent cytokine response.
Table 3. Cytokine Temporal Pattern in vivo vs. in vitro
Cytokine
Time to peak
in vivo Time to peak in vitro
Mean concentration
in vivo (ECF) (pg/ml)
Mean concentration
in vitro (supernatant) (pg/ml) Factor higher in vivo
TNF <24h – 19.0 1.5 12.7
IL7 Up to 24 h 1–72 h 46.7 26.1 1.8
IL8 Up to 24 h 24–72 h 5871 156 37.6
MIP1a Up to 36 h 72h 531 25.6 20.7
sCD40L Up to 48 h 72h 234 1.9 123
GRO Up to 48 h 24–72 h 1299 67.5 19.2
IL1b Up to 48 h – 16.5 1.4 11
PDGF AA Up to 48 h – 3690 418 8.8
MIP1b Up to 60 h 24–72 h 680 27.2 25
RANTES Up to 60 h 1–72 h 213 40.0 5.3
IL1ra 24–72 h 24h 208 10.2 20.4
IL6 24–72 h 24h 5789 289 20
G-CSF 24–72 h – 3650 5.2 702
IP10 24–72 h – 47345 709 66.8
IL12p70 96–144 h 1–72 29.7 3.5 8.5
IL10 96–144 h 24–72 h 73.0 9.1 8.0
TNF, tumor necrosis factor; IL, interleukin; MCP-1, monocyte chemotactic protein 1; sCD40L, soluble CD40 ligand; GRO, chemokine (C-X-C motif)
ligand 1; PDGF, platelet-derived growth factor; RANTES, regulated on activation, normal T cell expressed and secreted; G-CSF, granulocyte colony-
stimulating factor; IP-10/IP10, interferon gamma-induced protein 10.
Table depicts the temporal release patterns of some cytokines previously analyzed in the aftermath of human TBI,1 and concentrations seen in the
extracellular fluid after TBI.2 Time to peak describes when the highest concentrations could be seen after trauma or cytokine induction. The concentration
is compared between the brain extracellular fluid (ECF) as seen after TBI and in the culture supernatant. The factor higher concentration in vivo compared
with in vitro is noted.
1. Helmy, A., Carpenter, K.L., Menon, D.K., Pickard, J.D., and Hutchinson, P.J. (2011). The cytokine response to human traumatic brain injury:
temporal profiles and evidence for cerebral parenchymal production. J. Cereb. Blood Flow Metab. 31, 658–670.
2. Helmy, A., Guilfoyle, M.R., Carpenter, K.L., Pickard, J.D., Menon, D.K., and Hutchinson, P.J. (2014). Recombinant human interleukin–1 receptor
antagonist in severe traumatic brain injury: a phase II randomized control trial. J. Cereb. Blood Flow Metab. 34, 845–851.
8 THELIN ET AL.
in IL-7 levels. This suggests that there are distinct signature cyto-
kine release profiles in response to specific exogenous cytokine
triggers. For example, IL-6, TNF, and IL-1b, while they are usually
grouped together as ‘‘pro-inflammatory cytokines,’’ exert vastly
different effects in our paradigm.61,62 IL-1b and TNF signaling
work primarily through nuclear factor-jb (NFjb) translocation to
the nucleus where an array of inflammatory genes is activated in
response.63,64 While IL-6 has a comparable JAK-STAT andMAPK
nuclear translocation system, it can operate through either a trans-
membrane receptor or a soluble receptor, which greatly increases its
capacity.65 Similarly, TNF also has a soluble receptor that can in-
teract directly with cells,66 but which is not evident to the same
extent for IL-1b. Thus, the internal signaling and amplification
through soluble receptors might, in part, explain the differences in
secondary cytokine induction (and indeed level of induction), after
exposure to a defined primary cytokine stimulus.
Ensuing from our data analysis, three patterns of cytokine in-
duction are apparent where the first pattern is concentration de-
pendent, the second is time dependent but not concentration
dependent, and the third is both time dependent and concentration
dependent (Fig. 4 and Table 2). One would expect that if a cytokine
is induced, it will show dependency on the concentration of the
added cytokine if within the physiological range of stimulation, and
differences in concentration of the induced cytokine will be ap-
parent when the results for different added cytokines and obser-
vation time-points are compared.
Previous studies induced a cytokine response by adding IL-1b
and TNF to embryonic CNS cell mixed cultures12,57 and noticed
a dose- and time-dependent production of IL-6, IL-1b, and TNF
produced mainly by microglia. In comparison with our previous
in vivo work,8,24,26,43 while the sampling resolution was different,
many of the cytokines after TBI, (e.g., RANTES, IL-7, IL-8, GRO,
and MIP1b) seem to follow similar temporal trends in vitro as in
patients (Table 3).8 Hence, this in vitro model supports the time-
dependent endogenous production of cytokines.8 Moreover, all
cytokine concentrations measured were lower than in the in vivo
situation (Table 3), but for many, the ratio between in vivo and
in vitro was much higher suggesting that production of these cy-
tokines is predominantly driven by glial cells compared with oth-
ers.56 Cytokines with a lower ratio between in vivo and in vitro,
such as IL-8, could also suggest that neuronal production could
contribute in part. Microdialysis estimation of in vivo concentra-
tions also suffers from low relative recovery (proportion extracted
of the true extracellular concentration) of cytokines in comparison
with the in vitro situation where the ‘‘true’’ concentration can be
directly analyzed.8,23
Future studies, using co-cultured cells, can demonstrate the
different potency in cytokine production between glial and neuro-
nal cells. In summary, our study harnesses a human neuronal model
to gain clinically relevant insight into the temporal consequences of
exposure to key cytokines implicated in TBI.
Limitations
While IL-6 has been shown to induce the largest number of
cytokines in this model, this may stem from its use at several-fold
higher concentration than TNF and IL-1b. Moreover, when con-
firming the administered levels of IL-6 in the cultures (Fig. 3), the
maximum concentration added (1,000 ng/mL) exceeded the con-
centration range of the assay (*100 ng/mL), and therefore the
apparent result generated by the assay returns this upper limit value
at all time points. This increased concentration range was chosen,
however, based on human studies described previously, as to best
model the clinical conditions.8
Any in vitro model will not be representative entirely of the
in vivo situation, particularly in relation to interactions between
different cell types. In addition, the neuronal phenotype might
differ from what is seen in humans in vivo in a single cell type
enrichment culture. This is important particularly in the context of
the inflammatory response to trauma because microglia may be an
important driver of the balance between neurodegeneration and
neuroprotection.67,68 Nevertheless, what is lost in terms of the ac-
curacy from the model is gained in the interpretation of the results
in a highly defined and human system.
The choice of cytokines to measure is somewhat arbitrary;
however, they were chosen based on a wide screen of potential
mediators using multiplex technology. Importantly, they allow for
comparison with our clinical studies where the neuroinflammatory
response after TBI is assessed using down-stream cytokine re-
sponses in human subjects with TBI.8,24,26
The purity of the cultures used has been described previously in
detail.21 This is a key determinant of the interpretations drawn from
these data. Although we are confident of the high purity of the
neuronal culture used (approximately 84%, Fig. 1) and that the
cytokines thus have a neuronal origin, a minority of alternative cell
types, mainly neuronal precursors (approximately 13%) but also
some astrocytes (approximately 3%), could contribute to total cy-
tokine production. The lack of any substantial cytokine production
on addition of IL-1b, however, suggests that astrocytes were likely
not present to any great extent in the cultures.69 Moreover, mi-
croglia are effectively excluded from our cultures because of dif-
ferent developmental origins and thus divergent culture protocols
necessary to specify these cells. It would be possible to refine
cultures further using fluorescence-activated cell sorting (FACS)
techniques and appropriate antibodies. This would add physical
stress, however, including shearing forces, osmotic stress, and laser
damage,70 which would alter the cells and presumably induce or
modify a cytokine response. For future experiments, we will aim to
establish the exact origin of cytokines in terms of cell-type as well
as receptor expression of the affected cells.
The TGFb was the only cytokine that could not be measured at
any time point in the culture medium, while several other cytokines
appeared at low concentrations approaching the limit of sensitivity
of the Luminex assay. For example, at the 1-h time point, FGF2,
Flt3lig, GCSF, IL-2, IL-5, IL-15, and IL-17 appear to have very
consistent concentrations across all wells assayed. This is likely to
reflect the insensitivity of the assay at the lower limits of the
standard concentration curve, such that the fluorescence intensity is
interpreted as the lowest quantifiable standard. In this case, the
results are not interpretable. Because each time point was run on a
separate plate, the lower quantifiable limit may vary from time
point to time point.
We did not analyze cellular fate in the neuronal cultures after the
cytokine exposure. While this was not within the primary scope of
the study, it would have provided information about the state of the
cells or the rate of cellular death. We used relatively low concen-
trations of cytokines, however, compared with similar studies that
show cellular toxicity.16 For instance, similar concentrations of IL-
1b do not affect cellular viability above vehicle controls.51 For IL-6
and TNF, similar concentrations have even been shown to be
neuroprotective for retinal ganglion cells and enteric neurons,
respectively.71,72 Thus, while it is not possible to exclude the
possibility that some neurons might have succumbed because of
cytokine exposure, the available literature suggests that this is
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probably not the case, because of the relatively low concentrations
used in the present study.
Conclusions
This study has demonstrated a reproducible platform for ex-
amining a range of inflammatory mediators for their putative ef-
fects on enriched human neuronal cultures, providing a useful
comparator for data after human TBI. We found that a range of
cytokines is induced by the addition of IL-6 and TNF in a dose- and
time-dependent manner. Additional research is necessary to fully
explore the pathophysiological response after cytokine induction
in vivo and in vitro. Importantly, the patterns of cytokine response
we uncovered here are consistent with our in vivo experiments in
human subjects with TBI, thus validating our human stem cell-
derived neuronal platform as a clinically useful reductionist model.
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